2nd Quarter - Report — CEPHEID for CEPHEID (2016)

Firm

CEPHEID

Client

CEPHEID

Income

—

Expenses

$42,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Science/Technology SCI

molecular diagnostic tests, infection control platforms, regulation of laboratory tests, reimbursement for laboratory tests. antimicrobial resistance/antibiotic stewardship

Lobbyist	Covered position, as disclosed
MICHELE M SCHOONMAKER	—

Contacted: White House Office; SENATE; Agency for Healthcare Research & Quality (AHRQ); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Centers For Disease Control & Prevention (CDC); Veterans Affairs, Dept of (VA); Food & Drug Administration (FDA)

Health Issues HCR

Lobbying Issues: Molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance, antimicrobial resistance/antibiotic stewardship), hospital and other provider quality improvement programs CMS-related issues (reimbursement and coverage policies), FDA oversight of clinical laboratory tests, global health funding comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues, disease specific issues (multi-drug resistant tuberculosis, infection)

Lobbyist	Covered position, as disclosed
MICHELE M SCHOONMAKER	—

Contacted: Centers For Disease Control & Prevention (CDC); Agency for Healthcare Research & Quality (AHRQ); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; White House Office; SENATE; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Veterans Affairs, Dept of (VA)

Medicare/Medicaid MMM

Lobbying Issues: Molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance), hospital and other provider quality improvement programs CMS-related issues (reimbursement and coverage policies), FDA oversight, global health funding comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues

Lobbyist	Covered position, as disclosed
MICHELE M SCHOONMAKER	—

Contacted: SENATE; Food & Drug Administration (FDA); Centers For Disease Control & Prevention (CDC); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Veterans Affairs, Dept of (VA); White House Office; Agency for Healthcare Research & Quality (AHRQ); HOUSE OF REPRESENTATIVES

Medical/Disease Research/Clinical Labs MED

Lobbying Issues: Molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance), hospital and other provider quality improvement programs CMS-related issues (reimbursement and coverage policies), FDA oversight, global health funding comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues

Lobbyist	Covered position, as disclosed
MICHELE M SCHOONMAKER	—

Contacted: White House Office; Veterans Affairs, Dept of (VA); SENATE; HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Agency for Healthcare Research & Quality (AHRQ); Centers For Medicare and Medicaid Services (CMS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.